ghrp-2 vs ghrp-6
updated
ghrp-2 (tier D) vs ghrp-6 (tier D): what each is, why each got its grade, half-life and source counts side by side.
ghrp-2 · tier D
first-gen GH releaser. raises GH in short human studies. also spikes cortisol, prolactin, and hunger. ipamorelin replaced it.
tier rationale
D-tier because a cleaner alternative, ipamorelin, exists with the same core receptor target and less cortisol/prolactin baggage. Not F-tier because GHRP-2 works, it is a legitimate compound with a real mechanism and real effects, just worse than its direct successor for most GH-axis use cases. This is obsolete tier, not broken tier. With ipamorelin available as the cleaner comparator, the remaining niche is appetite stimulation rather than superior GH-axis signaling.
ghrp-6 · tier D
older sibling of GHRP-2. even more appetite, same cortisol issues. ipamorelin made it obsolete.
tier rationale
D-tier for the same reason as GHRP-2: a cleaner alternative (ipamorelin) exists at the same price and availability. Not F-tier because GHRP-6 does what it claims, pulsatile GH release, real appetite stimulation. The tier is about obsolescence, not failure. If ipamorelin didn't exist, this compound would be B-tier with specific cautions. With ipamorelin on the market and costing the same, the surviving niche is appetite stimulation, not a better GH-secretagogue profile.
at a glance
| ghrp-2 | ghrp-6 | |
|---|---|---|
| tier | D | D |
| category | gh / growth | gh / growth |
| sources | 23 | 15 |
| claims evaluated | 5 | 5 |
| half-life | approximately 15-60 minutes; short-acting pulsatile effect | approximately 15-60 minutes; short-acting pulsatile effect |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.